Published in Immunotherapy Weekly, October 1st, 2003
The agreement stipulates that the Guangdong Medicine Group Corp. (GMC) will conduct clinical trials with Alferon N Injection, a natural source, multispecies, alpha interferon product, for the treatment of HCV, and with Ampligen, a double-stranded RNA experimental compound acting potentially as an immunomodulator and antiviral, for the treatment of HIV. All costs related to these trials are covered by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.